Display options
Cite
Ladero JM, Agúndez JA, Martínez C, et al. Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk. Front Genet. 2012;3:278doi: 10.3389/fgene.2012.00278.
Ladero, J. M., Agúndez, J. A., Martínez, C., Amo, G., Ayuso, P., & García-Martín, E. (2012). Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk. Frontiers in genetics, 3278. https://doi.org/10.3389/fgene.2012.00278
Ladero, José M, et al. "Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk." Frontiers in genetics vol. 3 (2012): 278. doi: https://doi.org/10.3389/fgene.2012.00278
Ladero JM, Agúndez JA, Martínez C, Amo G, Ayuso P, García-Martín E. Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk. Front Genet. 2012 Dec 03;3:278. doi: 10.3389/fgene.2012.00278. eCollection 2012. PMID: 23420707; PMCID: PMC3572883.
Copy Download .nbib Format: NLM
Share it on

Front Genet. 2012 Dec 03;3:278. doi: 10.3389/fgene.2012.00278. eCollection 2012.

Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk.

Frontiers in genetics

José M Ladero, José A G Agúndez, Carmen Martínez, Gemma Amo, Pedro Ayuso, Elena García-Martín

Affiliations

  1. Service of Gastroenterology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos Madrid, Spain ; Department of Medicine, Medical School, Universidad Complutense Madrid, Spain.

PMID: 23420707 PMCID: PMC3572883 DOI: 10.3389/fgene.2012.00278

Abstract

In addition to the known effects on drug metabolism and response, functional polymorphisms of genes coding for xenobiotic-metabolizing enzymes (XME) play a role in cancer. Genes coding for XME act as low-penetrance genes and confer modest but consistent and significant risks for a variety of cancers related to the interaction of environmental and genetic factors. Consistent evidence supports a role for polymorphisms of the cytochrome P450 CYP2C9 gene as a protecting factor for colorectal cancer susceptibility. It has been shown that CYP2C8 and CYP2C9 overlap in substrate specificity. Because CYP2C8 has the common functional polymorphisms rs11572080 and rs10509681 (CYP2C8*3), it could be speculated that part of the findings attributed to CYP2C9 polymorphisms may actually be related to the presence of polymorphisms in the CYP2C8 gene. Nevertheless, little attention has been paid to the role of the CYP2C8 polymorphism in colorectal cancer. We analyzed the influence of the CYP2C8*3 allele in the risk of developing colorectal cancer in genomic DNA from 153 individuals suffering colorectal cancer and from 298 age- and gender-matched control subjects. Our findings do not support any effect of the CYP2C8*3 allele (OR for carriers of functional CYP2C8 alleles = 0.50 (95% CI = 0.16-1.59; p = 0.233). The absence of a relative risk related to CYP2C8*3 did not vary depending on the tumor site. We conclude that the risk of developing colorectal cancer does not seem to be related to the commonest functional genetic variation in the CYP2C8 gene.

Keywords: CYP2C8; biomarkers; colorectal cancer risk; polymorphisms; xenobiotic-metabolizing enzymes

References

  1. Gastroenterology. 2007 Jan;132(1):272-81 - PubMed
  2. Mol Carcinog. 2005 Sep;44(1):21-30 - PubMed
  3. Pharmacogenet Genomics. 2005 Aug;15(8):535-46 - PubMed
  4. Mol Diagn Ther. 2006;10(1):29-40 - PubMed
  5. Hum Mol Genet. 2008 Dec 1;17(23):3720-7 - PubMed
  6. Curr Drug Metab. 2008 Jul;9(6):520-31 - PubMed
  7. Br J Cancer. 2002 Sep 9;87(6):681-6 - PubMed
  8. Pharmacogenomics. 2006 Jun;7(4):575-85 - PubMed
  9. Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1460-7 - PubMed
  10. BMC Gastroenterol. 2005 Nov 10;5:34 - PubMed
  11. Farm Hosp. 2006 Jul-Aug;30(4):240-8 - PubMed
  12. BMC Clin Pharmacol. 2005 Oct 27;5:4 - PubMed
  13. Curr Drug Metab. 2004 Jun;5(3):211-24 - PubMed
  14. Pharmacogenet Genomics. 2005 Oct;15(10):713-21 - PubMed
  15. Clin Cancer Res. 2006 Nov 1;12(21):6585-9 - PubMed
  16. Neth J Med. 2009 Apr;67(4):134-41 - PubMed
  17. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20 - PubMed
  18. Pharmacogenomics J. 2008 Aug;8(4):237-47 - PubMed
  19. Pharmacogenet Genomics. 2010 May;20(5):315-26 - PubMed
  20. Nat Rev Cancer. 2006 Feb;6(2):130-40 - PubMed
  21. Am J Epidemiol. 2010 Nov 1;172(9):1000-14 - PubMed
  22. Curr Drug Metab. 2003 Aug;4(4):319-29 - PubMed
  23. Mutat Res. 1997 May 12;376(1-2):203-10 - PubMed
  24. Clin Gastroenterol Hepatol. 2004 Aug;2(8):704-12 - PubMed
  25. Neuromolecular Med. 2007;9(2):195-204 - PubMed
  26. Biochem Biophys Res Commun. 2002 Nov 22;299(1):25-8 - PubMed
  27. Carcinogenesis. 2002 Nov;23(11):1839-49 - PubMed
  28. Clin Pharmacol Ther. 2005 May;77(5):341-52 - PubMed
  29. Clin Chim Acta. 2007 May 1;380(1-2):191-6 - PubMed
  30. Clin Gastroenterol Hepatol. 2006 Jul;4(7):894-901 - PubMed
  31. Pharmacogenomics. 2009 Sep;10(9):1489-510 - PubMed
  32. Br J Clin Pharmacol. 2005 Jan;59(1):62-9 - PubMed
  33. Clin Pharmacol Ther. 2004 Aug;76(2):119-27 - PubMed
  34. Nat Genet. 2008 May;40(5):623-30 - PubMed
  35. Carcinogenesis. 2001 Aug;22(8):1323-6 - PubMed
  36. Bioorg Med Chem. 2012 Mar 15;20(6):2042-53 - PubMed
  37. Gastroenterology. 2009 Jun;136(7):2127-2136.e1 - PubMed
  38. Ann Oncol. 2012 Jun;23(6):1403-15 - PubMed
  39. Cancer Res. 2001 May 1;61(9):3566-9 - PubMed
  40. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3098-107 - PubMed
  41. Eur J Clin Pharmacol. 2001 Apr;57(1):47-9 - PubMed

Publication Types